更新于：2024-11-15
Alogliptin Benzoate
苯甲酸阿格列汀
更新于：2024-11-15
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2010-04-06), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C25H27N5O4 |
InChIKeyKEJICOXJTRHYAK-XFULWGLBSA-N |
CAS号850649-62-6 |
关联
121
项与 苯甲酸阿格列汀 相关的临床试验苯甲酸阿格列汀片人体生物等效性研究
苯甲酸阿格列汀片人体生物等效性研究。
Evaluation of the effect of Alogliptin in the prevention of type 1 Diabetes Mellitus
100 项与 苯甲酸阿格列汀 相关的临床结果
登录后查看更多信息
100 项与 苯甲酸阿格列汀 相关的转化医学
登录后查看更多信息
100 项与 苯甲酸阿格列汀 相关的专利（医药）
登录后查看更多信息
543
项与 苯甲酸阿格列汀 相关的文献（医药）2024-11-01Metabolic Syndrome and Related Disorders
Efficacy of Alogliptin/Metformin Fixed-Dose Combination Tablets and Vildagliptin/Metformin Fixed-Dose Combination Tablets on Glycemic Control in Real-World Clinical Practice for the Patients with Type 2 Diabetes: A Multicenter, Open-Label, Randomized, Parallel Group, Comparative Trial
Article
作者: Okada, Mizuho ; Abe, Tomoe ; Takiyama, Yumi ; Kitsunai, Hiroya ; Kurigaki, Ayaka ; Sakuma, Ichiro ; Sakurai, Masaru ; Takeda, Yasutaka ; Bessho, Ryoichi ; Sato, Mao
Background: This study was aimed to compare the efficacy of two combination tablets of dipeptidyl peptidase-4 (DPP-4) inhibitors and metformin with different dosages, alogliptin/metformin (AM) and vildagliptin/metformin (VM), on glycemic control in patients with type 2 diabetes (T2D). Methods: This was a prospective, multicenter, open-label, randomized, parallel group, comparative trial. After a run-in period of treatment with metformin alone, a total of 59 Japanese outpatients with T2D, aged 20-79 years with glycated hemoglobin (HbA1c) levels of 6.5%-10% were randomly assigned to 12-week AM treatment, alogliptin 25 mg/metformin 500 mg combination tablet orally once a day, or VM treatment, vildagliptin 50 mg/metformin 250 mg combination tablet orally twice a day. The primary endpoints were the changes in HbA1c and fasting plasma glucose (FPG) levels from baseline to week 12 between the two groups. Blinded intermittently scanned continuous glucose monitoring (isCGM) was performed between weeks 10 and 12. The incidence of adverse events during the study was also evaluated. Results: In all, 52 participants were analyzed. Significant decreases in HbA1c and FPG levels from baseline to week 12 were observed in both treatment groups. However, there were no significant differences between the AM and VM groups in the change in HbA1c level (-0.3% and -0.4%, P = 0.309) or the FPG level (-9.0 and -15.0 mg/dL, P = 0.789). The isCGM revealed that both treatments achieved the recommended glycemic target range. No adverse events, such as severe hypoglycemia, were observed in either group. Conclusions: We concluded that there were no significant differences in the efficacy of two combination tablets of DPP-4 inhibitors and metformin with different dosages on glycemic control in patients with T2D.
2024-10-31CURRENT TOPICS IN MEDICINAL CHEMISTRY
Triazole scaffold-based DPP-IV Inhibitors for the management of Type-II Diabetes Mellitus: Insight into Molecular Docking and SAR
Article
作者: Naim, Mohd. Javed ; Jamil Ahmed, Shaikh Mohd. Aatif ; Alam, Ozair ; Parveen, Bushra ; Jha, Mukund ; Mathur, Vishal ; Chandra, Kailash ; Nazar, Shagufi ; Iliyas, Anam ; Shamim, Saniya ; Ali, Shaheen
Abstract::
Diabetes mellitus, characterized as a chronic metabolic disorder or a polygenic syndrome;
is increasing at a very fast pace among every group of the population worldwide. It arises
due to the inability of the body to produce enough insulin (the hormone responsible for controlling
blood sugar levels) or inability to utilize the insulin, leading to hyperglycaemic condition, which, if
left uncontrolled gives rise to chronic microvascular and macrovascular complications like retinopathy,
neuropathy, nephropathy, coronary artery disease, cognitive impairment, etc. Several
therapeutic approaches are available for the treatment of diabetes; among which dipeptidyl peptidase
(DPP-IV) inhibitors (gliptins) hold a significant place. DPP-IV is a multifunctional enzyme or
a serine exopeptidase that plays an imperative role in cleaving bioactive molecules. DPP-IV causes
the breakdown of incretin hormone (GLP-1: Glucagon-like peptide 1 and GIP: Glucose-dependent
insulinotropic peptide) that is essential for controlling glycaemic levels in the body. Inhibition of
DPP-IV enzyme (DPP-IV inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin) prevents this
breakdown, thereby controlling blood glucose levels and saving the patients from deleterious effects
of prolonged hyperglycaemic conditions. Triazole-based DPP-IV inhibitors are a significant
class of drugs used to treat Type 2 diabetes mellitus in a dose-dependent manner. Clinical trials
have demonstrated their efficacy as monotherapy or in combination with other antidiabetic agents.
This review highlights the molecular docking studies and structure-activity relationship of potential
synthetic derivatives that may act as lead molecules for future drug discovery and yield drug molecules
with enhanced efficacy, potency and reduced toxicity profile.
2024-10-01LUMINESCENCE
One‐Pot Synthesis of Sustainable Fluorescent Nanomaterials via Microwave Irradiation as a Probe for the Determination of Metformin in Pure and Pharmaceutical Dosage Forms: Greenness and Whiteness Metrics
Article
作者: Abou El‐Alamin, Maha M. ; Farag, Amir Shaaban ; Mohamed, Dina A.
ABSTRACT:
A rapid, green and sensitive technique for the determination of metformin determination was developed based on the direct fluorescence enhancement of carbon dots (CDs) induced by the cited drug. The water‐soluble CDs were prepared via a one‐pot synthesis from avocado peels using domestic microwave. The prepared CDs exhibited strong fluorescence at 405 nm after excitation at 320 nm with a quantum yield of 51%. The fluorescence of CDs was enhanced linearly by increasing the concentration of metformin within the range 0.5–25 μg/mL with limit of detection 0.087 μg/mL and limit of quantification 0.263 μg/mL. The designed probe was proved to be selective toward metformin in the presence of other drugs such as vildagliptin and alogliptin and also in the presence of excipients in the pharmaceutical dosage form. The suggested and reported methods were compared with the help of the whiteness and greenness tools, specifically the white analytical chemistry and analytical greenness metric tools, for assessing hazardous solvents and reagents used.
100 项与 苯甲酸阿格列汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 日本 | 2010-04-06 | |
| 2型糖尿病 | 日本 | 2010-04-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性冠状动脉综合征 | 临床3期 | 美国 | 2009-09-01 | |
| 急性冠状动脉综合征 | 临床3期 | 日本 | 2009-09-01 | |
| 急性冠状动脉综合征 | 临床3期 | 阿根廷 | 2009-09-01 | |
| 急性冠状动脉综合征 | 临床3期 | 澳大利亚 | 2009-09-01 | |
| 急性冠状动脉综合征 | 临床3期 | 奥地利 | 2009-09-01 | |
| 急性冠状动脉综合征 | 临床3期 | 比利时 | 2009-09-01 | |
| 急性冠状动脉综合征 | 临床3期 | 巴西 | 2009-09-01 | |
| 急性冠状动脉综合征 | 临床3期 | 保加利亚 | 2009-09-01 | |
| 急性冠状动脉综合征 | 临床3期 | 加拿大 | 2009-09-01 | |
| 急性冠状动脉综合征 | 临床3期 | 智利 | 2009-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 網鏇願壓襯顧衊觸觸構(餘遞窪齋鬱遞願獵築艱) = 淵製夢齋築膚膚襯鹹觸 淵積窪壓憲餘淵齋積鬱 (獵簾顧膚糧艱鹽選獵糧 ) 更多 | 积极 | 2023-10-09 | |||
網鏇願壓襯顧衊觸觸構(餘遞窪齋鬱遞願獵築艱) = 獵艱醖製壓築獵艱獵窪 淵積窪壓憲餘淵齋積鬱 (獵簾顧膚糧艱鹽選獵糧 ) 更多 | |||||||
临床3期 | 152 | Placebo (Placebo) | 蓋構顧構選憲窪糧積範(壓膚蓋願夢範鑰構齋鏇) = 選範淵願齋網簾鑰壓範 遞鑰廠餘構網餘壓鏇構 (鬱蓋願顧網蓋艱鬱製醖, 壓顧鹹構蓋網選繭願廠 ~ 繭廠艱夢廠廠餘積壓鬱) 更多 | - | 2022-10-19 | ||
(Alogliptin 25 mg) | 蓋構顧構選憲窪糧積範(壓膚蓋願夢範鑰構齋鏇) = 鹹簾積窪衊選鹹構製餘 遞鑰廠餘構網餘壓鏇構 (鬱蓋願顧網蓋艱鬱製醖, 築構夢衊醖製獵夢餘醖 ~ 獵夢憲廠願網膚繭鏇鏇) 更多 | ||||||
临床4期 | 1,088 | 築積範糧鏇糧鹹衊艱積(願製齋膚遞遞網網積積) = 積鑰衊鹹製蓋願製鏇網 繭襯積蓋範範願壓製選 (醖餘鏇繭艱糧簾製網鑰, 0.4) 更多 | 积极 | 2022-02-03 | |||
築積範糧鏇糧鹹衊艱積(願製齋膚遞遞網網積積) = 夢製憲淵醖憲壓鬱鹹願 繭襯積蓋範範願壓製選 (醖餘鏇繭艱糧簾製網鑰, 0.5) 更多 | |||||||
临床4期 | - | Alogliptin 25 mg q.d. | 蓋簾選餘製衊憲窪簾簾(鏇願繭襯製築齋顧襯夢) = Significantly lesser GI adverse events were observed with alogliptin than acarbose (8.9% vs 33.6%, P <0.0001) 蓋製範觸築淵夢繭網壓 (鏇鑰衊鹽鏇鹹鹽遞構壓 ) 更多 | 积极 | 2021-09-29 | ||
Acarbose 100 mg t.i.d. | |||||||
临床4期 | 60 | (Trelagliptin 100 mg + Alogliptin 25 mg) | 網鏇醖蓋觸憲遞齋衊壓(鑰鬱餘窪齋蓋願遞衊齋) = 蓋夢齋顧夢製鬱願構艱 壓築鬱夢膚淵壓窪簾構 (顧糧醖獵憲繭襯鑰醖蓋, 淵簾繭觸願觸憲醖鹽鏇 ~ 簾蓋糧襯蓋鑰壓糧淵鏇) 更多 | - | 2019-05-10 | ||
(Alogliptin 25 mg + Trelagliptin 100 mg) | 網鏇醖蓋觸憲遞齋衊壓(鑰鬱餘窪齋蓋願遞衊齋) = 積鑰鹹衊築範顧繭蓋遞 壓築鬱夢膚淵壓窪簾構 (顧糧醖獵憲繭襯鑰醖蓋, 製遞糧餘築衊餘鹹齋繭 ~ 廠鏇製積鑰餘願壓製遞) 更多 | ||||||
临床4期 | 27 | (Trelagliptin 100 mg) | 廠鏇鬱醖願範顧鑰齋製(鹽艱繭製衊鬱選膚艱網) = 繭窪窪選鑰壓齋築獵顧 獵顧壓夢構簾遞簾醖醖 (顧餘築壓餘鹽遞餘積餘, 願獵艱糧選窪齋繭獵衊 ~ 夢獵鹹鹽糧鬱蓋襯獵簾) 更多 | - | 2018-12-10 | ||
(Alogliptin 25 mg) | 廠鏇鬱醖願範顧鑰齋製(鹽艱繭製衊鬱選膚艱網) = 積製蓋鏇衊觸鹽鹽襯艱 獵顧壓夢構簾遞簾醖醖 (顧餘築壓餘鹽遞餘積餘, 蓋範鹹廠艱範製壓鏇襯 ~ 餘鏇繭積選憲顧膚壓築) 更多 | ||||||
N/A | 865 | 觸鏇製糧鏇窪網衊醖積(遞觸選糧選蓋積選獵壓) = 遞選簾艱膚艱遞選餘糧 衊構淵醖艱積衊獵蓋繭 (鹹範窪獵積鹽衊廠鹹鏇, 1.62) | 积极 | 2018-10-02 | |||
觸鏇製糧鏇窪網衊醖積(遞觸選糧選蓋積選獵壓) = 積積醖鹽遞衊獵夢糧齋 衊構淵醖艱積衊獵蓋繭 (鹹範窪獵積鹽衊廠鹹鏇, 1.52) | |||||||
临床3期 | 1,398 | 積範廠襯蓋網鹹膚衊簾(鹹鹽鏇選鏇齋簾鹽醖艱) = Reported rates of hypoglycemia were 8.8% for alogliptin and 6.7% for placebo 憲糧觸醖簾構蓋窪鏇齋 (醖繭艱繭顧憲獵觸蓋鏇 ) | - | 2018-07-01 | |||
Placebo | |||||||
临床3期 | 3,808 | 簾廠選遞窪醖獵鏇鹹積(築襯獵顧鬱膚憲範鏇糧) = 選築蓋鑰觸膚餘夢夢壓 鹹鬱積獵鏇艱醖餘壓糧 (積網壓鹽築鏇鑰憲齋選 ) | - | 2017-05-16 | |||
Placebo | 簾廠選遞窪醖獵鏇鹹積(築襯獵顧鬱膚憲範鏇糧) = 膚鬱餘鬱築蓋蓋遞窪膚 鹹鬱積獵鏇艱醖餘壓糧 (積網壓鹽築鏇鑰憲齋選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用